UPDATES ON MANAGEMENT OF GASTRIC CANCER IN KOSOVO
2023
- 12Usage
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Usage12
- Abstract Views12
Artifact Description
One of the leading causes of cancer-related deaths worldwide is gastric cancer. In order to choose the best course of treatment for gastric adenocarcinoma, a multidisciplinary approach is essential. Systemic chemotherapy, radiation, surgery, immunotherapy, and targeted therapy have all demonstrated efficacy in this disease. The usual cytotoxic chemotherapy for localized disease may have reached a plateau with the acceptance of triplet chemotherapy for resectable gastric cancer. Molecular subtype classification of gastric cancer is opening the door to individualized treatment. Systemic therapy approaches are becoming more and more driven by biomarkers, particularly microsatellite instability (MSI), programmed cell death ligand 1 (PD-L1), human epidermal growth factor receptor 2 (HER2), tumor mutation burden, and Epstein-Barr virus. These biomarkers enable the identification of populations most likely to benefit from immunotherapy and targeted therapy. The less differentiated histologic subtypes of gastric cancer and those without indicators of immunotherapy activity nonetheless present significant research prospects.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know